PARP1 and prostate cancer: Although the use of Src family kinases (SFKs) inhibitors in prostate cancer cell lines has also been the subject of several publications, it is still not entirely clear which SFK member plays a dominant role in the transition to hormone independence in prostate cancer compared with PARP (10).